- Details
- Zachary Klaassen speaks with Sarah Psutka about cognitive resilience in bladder cancer care. Dr. Psutka explains how cancer treatment, from surgery to chemotherapy, can significantly impact cognitive function, with up to a third of patients experiencing persistent postoperative cognitive dysfunction. She emphasizes the shift from focusing solely on physical frailty to understanding patients' compl...
|
- Details
- Ashish Kamat talks with Andrea Apolo about implementing new treatment standards in bladder cancer, focusing on the recent EV-302 and CheckMate-901 trials. Dr. Apolo explains how enfortumab vedotin plus pembrolizumab has emerged as the new standard of care for metastatic urothelial carcinoma, showing superior survival outcomes compared to traditional platinum-based chemotherapy. They explore the ch...
|
- Details
- Seth Lerner discusses the SWOG study on standard versus extended lymphadenectomy for muscle-invasive bladder cancer published October 2024 in the New England Journal of Medicine. Dr. Lerner describes the trial's background, design, and key findings. The study, involving 592 patients with a median follow-up of 6.1 years, shows no benefit in disease-free or overall survival with extended lymphadenec...
|
- Details
- Thomas Powles discusses the EV-302 trial data, (Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer) focusing on biomarker analyses for enfortumab vedotin (EV) plus pembrolizumab in urothelial cancer. Dr. Powles discusses the lack of discriminatory effect for PD-L1 and nectin-4 expression as biomarkers, noting that nectin-4 is nearly universally expressed in urothelial can...
|
- Details
- Shilpa Gupta interviews Thomas Powles about the NIAGARA study, which examines perioperative chemoimmunotherapy in muscle-invasive bladder cancer. Dr. Powles discusses the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in event-free and overall survival. He emphasizes the study's practice-changing potential, noting the b...
|
- Details
- Leslie Ballas interviews Syed Hussain about histologic subtypes of bladder cancer. Dr. Hussain discusses the challenges in diagnosing and managing variant histologies, emphasizing their poor prognosis and the need for specialized research. He highlights the importance of central pathology review and the potential differences in treatment response among subtypes. Dr. Hussain advocates for focused i...
|
- Details
- Laura Bukavina joins Ashish Kamat to discuss the cancer microbiome and nutrition session at the BCAN Think Tank. Dr. Bukavina discusses key presentations on fecal microbiota transplants (FMT) in cancer treatment, highlighting promising results in lung cancer and melanoma. She emphasizes the potential of FMT to improve treatment responses and reduce toxicity. The conversation covers NCI funding opp...
|
- Details
- Sam Chang interviews Ignacio Duran about the highlights of ESMO 2024 in non-prostate genitourinary oncology. Dr. Duran discusses key findings in kidney and bladder cancer. For kidney cancer, he highlights studies challenging the sequencing of checkpoint inhibitors and new treatment options for non-clear cell carcinoma. In bladder cancer, Dr. Duran reviews three studies that could impact clinical p...
|
- Details
- Leslie Ballas and Tian Zhang discuss the STAR-EV trial, a new study combining enfortumab vedotin (EV) and radiation for muscle-invasive bladder cancer patients ineligible for cisplatin. Dr. Zhang outlines the trial's design, which uses three EV cycles followed by targeted radiation and cystectomy. The study aims to improve complete response rates from 36% with EV alone to 60% with the combination....
|
- Details
- Cora Sternberg discusses her presentation on event-free survival (EFS) as a surrogate endpoint for overall survival in muscle-invasive bladder cancer. Dr. Sternberg explains the study's methodology, which analyzed 15 clinical trials evaluating neoadjuvant treatments followed by radical cystectomy. The research demonstrates a strong association between EFS and overall survival, supporting EFS as a...
|
